United Therapeutics Corporation $UTHR Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 1.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 84,387 shares of the biotechnology company’s stock after selling 1,109 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.20% of United Therapeutics worth $45,728,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in United Therapeutics in the 2nd quarter valued at $2,868,735,000. Jupiter Topco LLC acquired a new stake in United Therapeutics during the second quarter worth about $450,140,000. Bank of New York Mellon Corp acquired a new position in shares of United Therapeutics during the second quarter worth about $159,522,000. Caisse de depot et placement du Quebec purchased a new position in shares of United Therapeutics in the second quarter valued at $154,304,000. Finally, Legal & General Group Plc purchased a new stake in United Therapeutics during the 2nd quarter worth approximately $112,209,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of recent analyst reports. The Goldman Sachs Group reiterated a “sell” rating and issued a $368.00 target price on shares of United Therapeutics in a research report on Thursday, October 15th. Bank of America cut their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $850.00 price target on shares of United Therapeutics in a research report on Monday, October 26th. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Finally, Morgan Stanley increased their price target on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 7th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $674.00.

Insiders Place Their Bets

In other news, CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $526.96, for a total value of $5,006,120.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $170,968,483.28. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 393,228 shares of company stock worth $207,340,321. 8.60% of the stock is owned by insiders.

United Therapeutics Stock Up 1.2%

Shares of NASDAQ:UTHR opened at $608.49 on Thursday. The stock has a market cap of $26.10 billion, a PE ratio of 21.77, a PEG ratio of 4.35 and a beta of 0.49. The company’s fifty day moving average is $532.33 and its 200 day moving average is $532.45. United Therapeutics Corporation has a 52 week low of $432.53 and a 52 week high of $614.23.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). The firm had revenue of $832.50 million during the quarter, compared to analysts’ expectations of $781.14 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The business’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the business earned $7.16 earnings per share. Sell-side analysts anticipate that United Therapeutics Corporation will post 26.09 EPS for the current year.

United Therapeutics declared that its Board of Directors has approved a stock buyback plan on Thursday, October 22nd that allows the company to repurchase $2 billion in outstanding shares. This repurchase authorization allows the biotechnology company to repurchase up to 8.3% of its stock through open market purchases. Share repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Third-quarter revenue rose 4.1% year over year to $832.5 million, beating analyst expectations of about $781 million. Management said the company is entering a period of stronger growth and advancing new therapies. United Therapeutics Q3 2026 results
• Positive Sentiment: BTIG raised its price target to $768 from $728 and maintained a Buy rating, signaling continued analyst confidence in the shares. BTIG Research ratings
• Positive Sentiment: The company announced a buyout of Pfizer’s royalty rights tied to ralinepag, a lung-disease therapy. Ending those royalties could improve the drug’s future economics, though the announcement details provided no financial terms. Ralinepag royalty buydown announcement
• Negative Sentiment: Adjusted earnings were a weak spot: EPS of $5.71 missed the approximately $6.01 consensus and fell from $7.16 a year earlier. Reports also noted lower net income. Q3 earnings miss
• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares, reducing her direct holding by 2.84%. She retained 324,443 shares; the sale may draw investor attention but does not by itself establish a change in the company’s outlook. United Therapeutics insider trades

United Therapeutics Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.